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Abstract 
 
Aims: Heart failure with preserved ejection fraction (HFpEF;収縮能が保持された心不全) is 
characterized by multiple comorbidities, including chronic kidney disease (CKD;慢性腎臓
病) that is one of prognostic risks for those patients.  This study was performed to evaluate 
the prognostic value of albuminuria using urine dipstick test (UDT;尿試験紙), combined with 
estimated glomerular filtration rate (eGFR;推算糸球体濾過量), for mortality in HFpEF. 
Methods and Results: I enrolled 2,465 consecutive patients with overt heart failure (HF;心不
全) with left ventricular ejection fraction (LVEF;左室駆出率) ³50% in our Chronic Heart 
Failure Analysis and Registry in the Tohoku District 2 (CHART-2;東北慢性心不全登録研
究) study (NCT00418041).  I defined ≥trace UDT as positive.  I divided them into the 
following 4 groups based on eGFR and UDT; Group 1 (G1) (eGFR≥60, negative-UDT), G2 
(eGFR≥60, positive-UDT), G3 (eGFR<60, negative-UDT), and G4 (eGFR<60, 
positive-UDT).  Totally, 29.5% of the HFpEF patients had positive-UDT.  HFpEF patients 
with positive-UDT were characterized by higher B-type natriuretic peptide (BNP;B型ナトリ
ウム利尿ペプチド) levels and frequent histories of hypertension or diabetes.  During a 
mean follow-up of 2.5 years, the HFpEF patients with positive-UDT showed higher mortality 
in each stratum of eGFR level.  Multivariable adjusted Cox model showed that when 
compared with G1 (reference), the hazard ratio of all-cause death for G2, G3 and G4 was 2.44 
(95% confidence interval 1.47-4.05, P=0.001), 1.43 (0.92-2.23, P=0.12), and 2.71 (1.72-4.27, 
P<0.001), respectively.  Furthermore, the prognostic value of positive-UDT was robust for 
both cardiovascular and non-cardiovascular deaths. 
Conclusions: These results indicate that measurement of albuminuria in addition to eGFR is 
useful for appropriate risk stratification in HFpEF patients.   
  
Keywords: heart failure with preserved ejection fraction, albuminuria, urine dipstick test, 
estimated glomerular filtration rate 
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I.  Introduction 
 
The prevalence of patients with heart failure with preserved ejection fraction (HFpEF;収縮能
が保持された心不全) has been rapidly increasing over the last 2 decades, whereas that of 
patients with HF with reduced ejection fraction (HFrEF;収縮能が低下した心不全) has been 
rather decreasing.1)  More than 50% of patients with the clinical syndrome of heart failure 
(HF;心不全) have a normal left ventricular ejection fraction (LVEF;.左室駆出率).1)  We 
have recently demonstrated that the prevalence of HFpEF has also increased in Japan in our 
HF cohort with 10,219 patients, named the Chronic Heart Failure Analysis and Registry in the 
Tohoku District 2 (CHART-2;東北慢性心不全登録研究) Study.2)  The increase in the 
number of HFpEF patients may be explained by the fact that the Japanese society has been 
rapidly aging and thus the proportion of elderly HF patients has also been rapidly increasing.3)  
Furthermore, the recent progress in reperfusion therapy has substantially contributed to 
preservation of LVEF after acute coronary events.4), 5) 
Although the survival of patients with HF improved during the last 2 decades among 
those with HFrEF, it did not improve among those with HFpEF.1)  Recent guidelines 
recommend the inclusion of objective evidence of diastolic dysfunction in diagnosing 
HFpEF,6) however, due to the pathophysiological heterogeneity of HFpEF, it is difficult to 
establish the uniform definition of the disorder.7)  Furthermore, there is no authorized 
treatment guidelines for HFpEF, although the prognosis of patients with HFpEF is equally 
poor compared with HFrEF patients.8)  Diagnostic methods for diastolic dysfunction using 
echocardiography is clinically difficult.  Therefore, simple diagnosing tools are needed for 
appropriate risk stratification in HFpEF patients. 
HFpEF is typically characterized by multiple comorbidities, (e.g., anaemia, chronic 
kidney disease (CKD;慢性腎臓病), chronic obstructive lung disease (COPD;慢性肺気腫), 
hyperuricemia, cerebrovascular disease, malignant tumor).9)  Among these comorbidities, 
the prevalence of CKD is higher than other diseases.9)  Furthermore, CKD is associated with 
anaemia, hyperuricemia, and cerebrovascular disease.  Therefore, CKD may be the most 
important comorbidities in HFpEF patients.  Moreover, the effective treatment of CKD may 
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be more essential in HFpEF than in HFrEF.10) 
Albuminuria is a well-known independent risk factor for mortality in the general 
population,11) hypertension,12) and diabetes,13) reflecting glomerular injury, systemic 
inflammation, and activation of renin-angiotensin system (RAS;レニンアンギオテンシン
系).  Therefore, the use of urine albumin to creatinine ratio (UACR;尿中アルブミンクレア
チニン比) is currently emphasized to evaluate the severity of CKD.14)  However, the 
severity of CKD is usually defined by reduced estimated glomerular filtration rate (eGFR;糸
球体濾過量).  In HF patients, it has reported that the prevalence of the patients with 
albuminuria (≥30 mg/g) was about 30%.15), 16)  Furthermore, HF patients with albuminuria 
(≥30 mg/g) had poorer prognosis.16)-19)  However, most of HF patients included in these 
studies were HFrEF.   
  The aim of this study was to evaluate the prognostic value of albuminuria using 
UDT combined with eGFR in HFpEF patients in our CHART-2 Study. 
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II. Methods 
 
1. Population and inclusion criteria 
Details of the design, purpose, and basic characteristics of the CHART-2 Study have been 
described previously (NCT00418041).2)  Briefly, eligible patients were aged ≥20 years with 
significant coronary artery disease or in the stage B, C or D defined by the Guidelines for the 
Diagnosis and Management of Heart Failure in Adults authorized by the American College of 
Cardiology Foundation (ACC;米国心臓病学会) / American Heart Association (AHA;米国心
臓協会).20)  Patients were classified as having HF by experienced cardiologists using the 
criteria of the Framingham Heart Study.21)  There were no other exclusion criteria in the 
study.  The present study was approved by the local ethics committee in each participating 
hospital.  Eligible patients were consecutively recruited after written informed consent was 
obtained.  The CHART-2 Study was started in October 2006 and the entry period was 
successfully closed in March 2010 with 10,219 patients registered from the 24 participating 
hospitals.  All data and events will be surveyed at least once a year until March 2013. 
In the CHART-2 Study, LVEF was measured by echocardiography at the time of 
enrollment.  In the present study, patients with LVEF≥50% were classified as having HFpEF, 
whereas those with LVEF<50% as having HFrEF.1)  The study flow diagram is shown in 
Figure 1.  In the present study, I excluded the patients in stage B and those with severe 
valvular heart disease (VHD;弁膜症), congenital heart disease, pulmonary arterial 
hypertension, pericardial disease or on hemodialysis (Figure 1).  Severe VHD was defined 
by the Guidelines for the management of patients with VHD authorized by the ACC/AHA.22)  
Severe aortic valve stenosis was defined as follows; jet velocity was greater than 4.0m/second 
or valve area was less than 1.0cm2.  Severe aortic regurgitation was defined as follows; color 
doppler jet width was greater than 65% of left ventricular outflow tract or doppler vena 
contracta width was greater than 0.6cm.  Severe mitral stenosis was defined as follows; 
mean pressure gradient was greater than 10mmHg or valve area was less than 1.0cm2.  
Severe mitral regurgitation was defined as follows; vena contracta width was greater than or 
equal to 0.7cm or jet area was greater than 40% of left atrial area.  I also excluded patients 
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who did not have UDT measurement.  Therefore, 2,465 HFpEF patients were finally 
included in the present study (Figure 1). 
 
2. Measurements of albuminuria  
Albuminuria in the study population was qualitatively evaluated using UDT.  Eight kinds of 
UDTs marketed by 5 medical corporations were used in the participating hospitals.  The 
name of the corporation and percentage of patients were as follows; ARKLEY, Inc., Kyoto, 
Japan (39.4%), Eiken chemical Co. Ltd., Tokyo, Japan (26.2%), SIEMENS AG, Munich, 
Germany (21.9%), SYSMEX Corporation, Kobe, Japan (8.6%), Roche Diagnostics, Basel, 
Switzerland (3.6%) and unknown, 0.4%.  All UDTs were calibrated to indicate 1+ 
qualitatively at urine protein concentration of ≥0.3 g/L.  Detections of proteinuria on 
dipsticks of the 4 corporations (ARKELEY, Siemens AG, Eiken Chemical, and SYSMEX) 
were calibrated to indicate trace at ≥0.15 g/L, ≥0.1 g/L, ≥0.15 g/L, and ≥0.1g/L of 
proteinuria, respectively.  Dipstick marketed by Roche Diagnostics did not originally 
indicate trace on proteinuria. 
It has been reported that trace proteinuria evaluated by UDT could be a useful 
indicator of albuminuria (≥30 mg/g) in the subjects at high risk of cardiovascular disease.23)  
Furthermore, a recent report denoted that trace UDT could identify urine albuminuria (≥30 
mg/g) with high specificity and negative predictive value.24)  Thus, in the present study, I 
defined positive-UDT for proteinuria as ≥trace and the other as negative-UDT. 
 
3. Renal function 
Estimated GFR (ml/min/1.73m2) was calculated using the modified Modification of 
Diet in Renal Disease equation with the Japanese coefficient25) at the time of enrollment as 
follows; GFR (ml/min per 1.73 m2) = 186 × Creatinine−1.154 × Age−0.203× 0.742 (if female) × 
1.233.  I defined reduced eGFR as <60 ml/min/1.73m2 according to the guideline. 14) 
 
4. Follow-up survey and study outcomes 
I conducted the first survey of survival in August 2010 and the mean follow-up period of the 
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study population was 2.5±1.0 [SD] years.  The outcomes of this study included all-cause 
death, cardiovascular death (CVD;心血管死), and non-cardiovascular death (NCVD;非心血
管死).  CVD was defined as deaths due to myocardial infarction, HF, cerebrovascular 
disease, aortic aneurysm rupture and sudden death.  Deaths other than CVD were classified 
as NCVD.  Mode of death was determined by the attending physician and was confirmed by 
one independent physician who was a member of the Tohoku Heart Failure Association.2 
 
5. Statistical analysis 
To evaluate the usefulness of UDT, I divided the 2,465 patients into the following 4 groups; 
Group 1 (G1) with normal eGFR with negative-UDT (N=1,043), G2 with normal eGFR with 
positive-UDT (N=342), G3 with reduced eGFR with negative-UDT (N=703), and G4 with 
reduced eGFR with positive-UDT (N=386) (Figure 1). 
Comparisons of data among the 4 groups were performed by ANOVA test for 
continuous variables and by chi-square test for dichotomous variables.  Continuous data 
were described as mean ± standard deviation (SD;標準偏差).  Kaplan-Meier curves were 
plotted to evaluate the association between the results of UDT and all-cause death, CVD and 
NCVD.   
I also constructed the following 4 Cox proportional hazard regression models; (a) 
unadjusted, (b) age- and sex- adjusted, (c) adjusted by the clinical status and comorbidities in 
addition to the model (b), and (d) fully adjusted including medical treatments.  In the model 
(c), I included the following covariates that potentially influence the outcomes; age, sex, New 
York Heart Association class, history of admission for HF, body mass index, systolic blood 
pressure,26) heart rate,27) serum sodium, serum potassium, comorbidities26) (anemia defined as 
hemoglobin <12 g/dL in females and <13 g/dL in males, diabetes mellitus, hyperuricemia, 
atrial fibrillation, history of coronary artery disease, cerebrovascular disease, and malignant 
tumor) and brands of UDT.  In the model (d), I included treatment (b-blocker, RAS 
inhibitors, calcium channel blockers, loop diuretics, and aldosterone antagonists) in addition 
to model (c).  Finally, to determine the prognostic value of UDT in addition to eGFR, I 
constructed Cox proportional hazard models in patients with ≥60 or <60 of eGFR separately 
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including all covariates in the model (d) plus eGFR level.   
All statistical analyses were performed using SPSS Statistics 19.0 (SPSS Inc. 
Chicago, Illinois, USA) and statistical significance was defined as a 2-sided P value less than 
0.05.  
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III. Results 
 
1. Baseline characteristics (Table 1) 
Mean age was 69.6±11.7 years and male patients accounted for 68.2% in the study population.  
Coronary artery disease was observed in 52.1% and the mean LVEF and eGFR were 
65.3±9.0% and 62.4±24.3 ml/min/1.73m2, respectively.  The prevalence of CKD patients, 
defined as eGFR<60 ml/min/1.73m2, was 44.1% (N=1,089).  The prevalence of the patients 
with positive-UDT was 29.5% (N=728).  Furthermore, the prevalence of the patients with 
positive-UDT and with eGFR<60 was higher (35.4%, N=386) than that of the patients with 
positive-UDT and with eGFR≥60 (24.9%, N=342).  The patients with trace proteinuria 
accounted for the largest part of those with positive urine dipsticks.  Male and older patients 
had higher prevalence of positive-UDT.  Furthermore, the patients with eGFR<60 had 
severer positive urine dipstick results compared with those with eGFR≥60. 
The patients with reduced eGFR (G3 and G4) were characterized by older age, 
higher prevalence of HF admission.  Furthermore, they had lower hemoglobin level, and 
were more likely to be taking furosemide, angiotensin II receptor blocker, and calcium 
channel blocker.  The G1 and G3 patients had a negative-UDT.  The patients in G1 who had 
normal eGFR were characterized by younger age and had the lowest B-type natriuretic 
peptide (BNP;B型ナトリウム利尿ペプチド) level compared with other groups.  The G3 
patients who had reduced eGFR were characterized by more female compared with other 
groups.  There were no differences in the prevalence of past history of coronary artery 
disease, atrial fibrillation, body mass index, LVEF or the usage rate of b-blocker among the 4 
groups.  However, some baseline characteristics of patients with positive-UDT were 
different from those with negative-UDT.  Regardless of the existence of CKD, HFpEF 
patients with positive-UDT (G2 and G4) were characterized by higher prevalence of 
hypertension, diabetes mellitus, past history of HF admission, and cerebrovascular disease 
compared with those with negative-UDT.  Furthermore, those with positive-UDT were 
associated with higher systolic blood pressure, elevated heart rate and higher BNP level. 
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2. Impact of positive urine dipstick test for all-cause death 
During the mean follow-up period of 2.5±1.0 years, 213 patients (8.6%) died.  Eight patients 
(0.3%) were lost to follow up.  Figure 2A shows Kaplan-Meier survival curves for all-cause 
death.  Groups with positive-UDT (G2 and G4) had poorer prognosis than those with 
negative-UDT (G1 and G3) within each stratum of eGFR (both P<0.001).  Importantly, 
patients with positive-UDT and normal eGFR (G2) showed significantly poorer prognosis 
compared with those with negative-UDT and normal eGFR (G1).   
Table 2 shows the results of multivariable Cox proportional hazard regression 
analysis for all-cause death (the upper portion).  In the unadjusted model (a), as compared 
with G1 (reference), G2, G3 and G4 showed 202%, 239% and 500% increase in the risk for 
all-cause death, respectively (all P<0.001).  In the model (c), as compared with G1, the 
hazard ratios (HRs) (95% CI) for all-cause death of G2, G3 and G4 were 2.60 (1.59-4.24), 
1.47 (0.94-2.27), and 2.63 (1.67-4.13), respectively.  Importantly, the significance of HRs for 
all-cause death in G2 and G4 remained robust after the adjustment by HF treatments in the 
model (d). 
 
3. Impact of positive urine dipstick test for cardiovascular and non-cardiovascular 
death 
Of the 213 deaths noted, 86 (40.4%) were due to cardiovascular cause.  Figure 2B shows 
Kaplan-Meier survival curves for CVD.  G2 showed significantly higher cardiovascular 
mortality compared with G1 (P<0.001).  However, there was no significant difference in 
CVD between G3 and G4.  Table 2 shows the results of multivariable Cox proportional 
hazard regression analysis for CVD (the middle portion).  In the fully adjusted model (d), as 
compared with G1 (reference), the HRs (95% CI) for CVD of G2, G3 and G4 were 3.58 
(1.50-8.58), 2.34 (1.10-4.98), and 3.29 (1.48-7.31), respectively.  Importantly, the 
significance of HRs for CVD in G2 and G4 remained robust in the model (b), (c) and (d). 
NCVD were observed in 127 patients during the study period.  Thirty nine patients 
(30.7%) died from malignant tumor.  Furthermore, 34 patients (26.8%) died from infectious 
disease.  Figure 2C shows Kaplan-Meier survival curves for NCVD.  Groups with 
Miura M et al. Page 11 
positive-UDT had significantly higher NCVD than those with negative-UDT within each 
stratum of GFR (both P<0.001).  Table 2 shows the results of multivariable Cox 
proportional hazard regression analysis for NCVD (the lower portion).  In the model (a), as 
compared with G1 (reference), the HRs (95% CI) for NCVD of G2, G3 and G4 were 2.75 
(1.52-4.98), 2.41 (1.45-4.01) and 5.37 (3.26-8.83), respectively.  However, in the models 
(b), (c) and (d), the HRs for NCVD in G3 was not significantly higher compared with those 
in G1 (Table 2).  Again, the significance of HRs for NCVD in G2 and G4 remained robust 
in the model (b), (c) and (d).   
 
4. Prognostic importance of urine dipstick test in addition to eGFR 
About one third of the HFpEF patients in the present study had positive-UDT.  Figure 3 
shows the results of Cox proportional hazard regression analysis for eGFR≥60 or <60 
adjusted by the covariates including eGFR.  In the HFpEF patients with eGFR≥60, as 
compared with G1, G2 showed 227%, 293% and 216% increase in the risk for all-cause death, 
CVD and NCVD, respectively (all P<0.001).  In the HFpEF patients with eGFR<60, as 
compared with G3, G4 showed 174% and 212% increase in the risk for all-cause mortality 
and NCVD, respectively, whereas there was no significance for CV death. 
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IV. Discussion 
 
The novel findings of the present study are the follows.  First, about 30% of the HFpEF 
patients had positive-UDT.  Second, the HFpEF patients with positive-UDT had significant 
higher mortality as compared with those with negative-UDT in each stratum of eGFR levels.  
Third, prognostic impact of positive-UDT was significantly enhanced after adjusted by the 
covariates including eGFR.  These findings indicate that we need to perform UDT in 
addition to eGFR in all HFpEF patients for appropriate risk stratification. 
 
1. Albuminuria as a marker of cardiorenal syndrome in HFpEF 
Albuminuria is known as an independent risk factor for mortality in general population and in 
patients with hypertension or diabetes.11)-13)  In HF patients, the prevalence of the patients 
with albuminuria (≥30mg/g) was about 30%.15),16)  Furthermore, HF patients with 
albuminuria (≥30mg/g) had poorer prognosis independent of diabetes, hypertension, or renal 
function.16)-19)   Anand et al. reported that proteinuria was associated with abnormal physical 
findings and clinical indicators of volume overload, which suggests that a possible pathogenic 
role of increased intravascular volume.17)  Furthermore, RAS-activation and inflammation 
have been suggested to play causal roles in increasing albuminuria.19)  Therefore, HF 
patients with albuminuria (≥30mg/g) may have higher RAS-activity compared with those 
without albuminuria.  However, most of HF patients included in these studies were HFrEF. 
To our knowledge, this is the first report describing the relationship between HFpEF 
and albuminuria using UDT.  In HFpEF patients, the prevalence of albuminuria (≥30mg/g) 
was almost similar to that of HFrEF.  Furthermore, HFpEF patients with positive-UDT had 
significant poorer prognosis.  The mechanisms linking albuminuria and HFpEF remain 
unknown.  However, there may not be large difference between HFrEF and HFpEF about the 
mechanism of elevated albuminuria. 
CKD is a frequent complication of HF and this close association has been called the 
cardiorenal syndrome (CRS).28)  Both CKD and HF are associated with an increased activity 
of sympathetic nervous system and RAS-activation, oxidative stress, and inflammation.28)  
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Therefore, we usually pay attention to renal function in HF patients.  Compared with HFrEF 
patients, HFpEF patients were considered to have smaller RAS-activity.29)  However, 
according to the pathophysiology of elevated albuminuria in HF patients, HFpEF patients 
with albuminuria (≥30mg/g) may have higher RAS-activity than those with normal 
albuminuria.  Therefore, the linkage between heart and kidney in HFpEF patients with 
albuminuria (≥30mg/g) may be larger than those in HFpEF patients without normal 
albuminuria.  So, the measurement albuminuria is essential to evaluate CRS in addition to 
eGFR in all HF patients. 
 
2. Benefit of the combination of eGFR and UDT in predicting the prognosis 
Although guidelines for the classification and staging of CKD are based on eGFR, the use of 
UACR is currently emphasized for the assessment of CKD.14)  However, most physicians 
may consider that albuminuria measurement is not so convenient even in HF patients.  In 
most clinical settings, eGFR is calculated by age, sex and serum creatinine.25)  HFpEF 
patients usually tend to be older and female.1)  Therefore, some HFpEF patients may indicate 
eGFR<60 without significant renal damage.  Indeed, in the present study, the HFpEF 
patients in G3 were older and more female as compared with other groups.  The present 
result shows that HFpEF patients with negative-UDT tend to have better prognosis than those 
with positive-UDT. 
UDT has been widely used as an initial screening method for evaluation of 
proteinuria on the basis of low cost and the ability to provide rapid point-of-care information 
to clinicians and patients.24)  Furthermore, UDT is most sensitive to albumin but is less 
sensitive to globulins and secreted proteins.24)  Konta et al. has reported the significant 
usefulness of ≥trace UDT to predict albuminuria (≥30 mg/g) in the general population.23)  
Furthermore, the negative predictive value of UDT for identification of albuminuria (≥30 
mg/g) was higher than the threshold of ≥1+.23)  Thus, in the present study, I defined 
positive-UDT for albuminuria when the analysis showed ≥trace.  Albuminuria (≥30 mg/g) is 
observed in approximately one third of HF patients.15),16)  In the present study, the prevalence 
of patients with positive-UDT with normal eGFR and those with reduced GFR was 24.9% and 
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35.4%, respectively.  Thus, our findings indicate that positive-UDT is useful for detection of 
albuminuria and could be a reasonable surrogate of UACR measurement in HFpEF patients. 
In HFpEF patients with eGFR ≥60, those with positive-UDT showed about twice 
higher mortality than those with negative-UDT.  Furthermore, in the HFpEF patients with 
eGFR<60, those with positive UDT also showed significantly higher mortality compared with 
those with negative-UDT.  This result indicates that we should perform UDT in addition to 
eGFR evaluation in HFpEF patients regardless of eGFR. 
 
3. Implications of positive urine dipstick test in HFpEF 
The reason of the poorer prognosis of HFpEF patients with positive-UDT remains to be fully 
clarified.  In the present study, the HFpEF patients with positive-UDT were characterized by 
higher BNP level, suggesting that venous filling pressure is significantly increased.  Venous 
congestion could cause proteinuria in dogs,30) implicating that elevated venous pressure may 
be associated with the development of albuminuria.  Furthermore, albuminuria may 
attenuate the effect of furosemide because filtered albumin may bind furosemide in the 
tubular fluid and impair the interaction with the luminal co-transporting proteins.31)  
Resistance to diuretics may deteriorate venous congestion status with a resultant vicious cycle 
of albumin excretion into urine.  Thus, the therapeutic strategy for reducing albuminuria is 
important in HFpEF patients. 
In the present study, 40% of deaths were caused by cardiovascular events.  Zile et al. 
also reported that 60% of deaths in HFpEF patients were CVD.32)  Albuminuria reflects 
glomerular injury, systemic inflammation and endothelial dysfunction that lead to 
cardiovascular events.16)  Furthermore, albuminuria has been associated with changes in 
coagulation factors.33)  In the present study, the rate of CVD was relatively low; however, 
positive-UDT could predict CVD in HFpEF patients, especially in those with normal eGFR.  
In HFpEF patients with eGFR<60, the patients with positive-UDT showed no significant 
difference in the development on CVD compared with those with negative-UDT.  This result 
indicated that the influence of eGFR decline on CVD may be larger than albuminuria in the 
patients with eGFR<60.  However, Perkins et al. reported that cases of early eGFR decline 
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occurred in 9% of the normal albuminuria group and 31% of the albuminuria (≥30mg/g) 
group in diabetes patients.34)  Therefore, in the follow-up period, there may be a considerable 
eGFR decline in the patients with positive-UDT compared with those with negative-UDT that 
leads to poor outcome.  So, we need to perform UDT in addition to eGFR even in HFpEF 
patients with eGFR<60. 
In the present study, positive-UDT was also associated with increased NCVD, a 
consistent finding with the previous report by Hillege et al.33)  Approximately one third of the 
NCVD were due to malignant tumors in the present study.  Although the underlying 
mechanisms remain to be elucidated, patients with advanced malignant tumor have a 
significantly higher urinary albumin excretion rate than those with localized disease.35) 
In the present study, the remaining one third of NCVD was due to infectious diseases. 
HFpEF patients with albuminuria tended to accompany with cerebrovascular disease that lead 
to impaired activities of daily living (Table 1).  Such patients are particularly at high risk of 
infectious disease.  The present results also indicate that the prevention for infectious 
diseases and cerebrovascular disease are important to reduce the mortality of HFpEF patients.  
 
4. Treatment strategy of HFpEF patients with positive urine dipstick test 
The underlying mechanisms of the close relationship between the heart and the kidney 
include inflammation and activated RAS and/or sympathetic nervous system.16)  Importantly, 
these mechanisms are also involved in the pathogenesis of albuminuria.16)  It was reported 
that RAS inhibitors cause a significant decrease in albuminuria and a trend of decrease in 
cardiovascular events in patients with hypertension, left ventricular hypertrophy and 
diabetes.36)  On the other hand, RAS inhibition in HFpEF is not associated with consistent 
reduction in HF admission nor mortality.29)  The overall failure of RAS inhibitors to improve 
morbidity and mortality of HFpEF patients suggest a relatively smaller contribution of 
neurohumoral activation on HF progression as compared with HFrEF patients.29)  However, 
the HFpEF patients with positive-UDT may have higher RAS activity than those with 
negative-UDT.   It was reported that telmisartan treatment was associated with an increased 
risk of adverse renal events in patients without albuminuria, whereas it tended to improve 
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outcomes of patients with albuminuria.37)  Thus, baseline albuminuria level may be an 
important factor when selecting patients for the treatment with RAS inhibitors.38)  Again, the 
importance of UDT should be emphasized before we start to use RAS inhibitors for HFpEF 
patients. 
 We need to consider other therapeutic options for HFpEF patients in addition to RAS 
inhibitors.  Carvedilol, a beta blocker with antioxidant effects, exerts a greater therapeutic 
effects for albuminuria as compared with metoprolol.39)  Spironolactone, an aldosterone 
antagonist, also exerts a beneficial effect for albuminuria.39)  Thus, standard therapy for HF 
may be needed to improve long-term prognosis of HFpEF patients with positive-UDT. 
 
5. Study limitations  
Several limitations should be mentioned for the present study.  First, I had no information 
other than LVEF on left ventricular function, and it therefore remains unknown whether the 
study population had objective evidence of diastolic dysfunction recommended by the recent 
guidelines in the diagnosis of HFpEF.6)-8)  Second, in the present study, UDTs from 5 
different companies were used in the participating hospitals.  Four dipsticks were calibrated 
to indicate trace at ≥0.1 g/L or ≥0.15 g/L of proteinuria and 1 dipstick did not indicate trace 
originally.  Furthermore, sensitivity and specificity for detecting albuminuria may be 
different among these dipsticks.  However, multivariate analyses including all covariates 
with the UDT brands clearly showed the significant prognostic impact of positive-UDT in 
HFpEF patients.  Third, the present results were analyzed by data collected at the entry of 
subjects and I did not take into consideration the possible changes in UDT during the 
follow-up period.  Fourth, the primary design of the present study did not cover chronic lung 
disease, which has been recognized as one of the important prognostic factors of HFpEF.9)    
Finally, since the CHART-2 study is an observational study, the present results need to be 
carefully interpreted especially when the effects of treatment are evaluated. 
  
V. Conclusions 
The present results demonstrate that albuminuria predicts the mortality of HFpEF patients in 
Miura M et al. Page 17 
each stratum of eGFR levels, suggesting its usefulness for appropriate risk stratification in 
those patients. 
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Figure Legends 
 
Figure 1. Study flow diagram. 
 
Figure 2. Kaplan-Meier survival curves for all cause death (A), cardiovascular death (B), and 
non-cardiovascular death (C).  The 4 groups were categorized based on eGFR and urine 
dipstick test (UDT); Group 1 (G1) (eGFR≥60, negative-UDT), G2 (eGFR≥60, positive-UDT), 
G3 (eGFR<60, negative-UDT) and G4 (eGFR<60, positive-UDT). 
 
Figure 3. Hazard ratios for all-cause death, cardiovascular death, and non-cardiovascular 
death after adjustment by multiple covariates including eGFR.  (A) eGFR≥60 (G2 vs. G1), 
(B) eGFR<60 (G4 vs. G3). HR, hazard ratio; 95%CI, 95% confidence interval. 
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Table 1.  Baseline characteristics of the study patients. 
  Group 1 Group 2 Group 3 Group 4   
  N = 1034 N = 342 N = 703 N = 386   
↓eGFR - - + +   
Dipstick negative positive negative positive P value 
Age (yrs.) 66.2 ± 11.8  67.3 ± 12.4  73.9 ± 9.5  73.1 ± 10.8  < 0.001 
Male (%)  69.4  76.3  62.2  68.9  < 0.001 
History of admission for HF (%)  38.8  48.4  53.1  56.1  < 0.001 
Comorbidities (%)                           
  Hypertension 70.8  75.6  76.4  85.1  < 0.001 
  Diabetes  22.0  29.2  21.6  33.2  < 0.001 
  Hyperuricemia  26.0  26.6  55.0  60.1  < 0.001 
  Atrial fibrillation 27.8  33.0  35.2  31.7  0.05 
  Coronary artery disease 52.2  48.5  51.1  56.7  0.15 
  Cerebrovascular disease  12.2  16.7  19.8  21.5  < 0.001 
  Malignant tumor 9.5  12.0  13.1  13.2  0.10  
Clinical status                        
  NYHA class 3 and 4 (%)  6.3  5.6  12.1  11.5  < 0.001 
  Body mass index (kg/m2)  23.9 ± 4.5  23.9 ± 5.6  23.7 ± 4.7  23.7 ± 4.4  0.87 
  Systolic blood pressure (mmHg)  127.4 ± 17.1  131.8 ± 18.9  127.6 ± 19.2  133.4 ± 20.1  < 0.001 
  Diastolic blood pressure (mmHg)  74.1 ± 11.1  75.1 ± 12.6  71.7 ± 12.3  72.5 ± 12.1  < 0.001 
  Heart rate (beat/min) 70.9 ± 13.9  73.6 ± 15.8  70.7 ± 13.8  72.5 ± 12.1  0.003 
Measurement                        
  LVEF (%)  65.2 ± 9.0  65.0 ± 9.4  65.7 ± 9.1  64.8 ± 8.5  0.40  
  LVDd (mm) 48.8 ± 6.9  49.0 ± 7.3  48.7 ± 7.5  49.1 ± 7.4  0.74 
  Hemoglobin (g/dL)  13.7 ± 1.7  13.8 ± 2.4  12.7 ± 2.0  12.2 ± 2.1  < 0.001 
  Blood urea nitrogen (mg/dL)  15.3 ± 4.2  15.5 ± 4.1  22.3 ± 8.8  26.2 ± 12.0  < 0.001 
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  Serum sodium (mEq/L) 141.0 ± 2.6  140.9 ± 2.9  140.9 ± 2.8  141.2 ± 3.2  0.40  
  Serum potassium (mEq/L) 4.3 ± 0.4  4.2 ± 0.4  4.5 ± 0.5  4.4 ± 0.5  < 0.001 
  Serum albumin (g/dL) 4.2 ± 0.4 4.1 ± 0.5 4.1 ± 0.4 3.9 ± 0.6 < 0.001 
  GFR (ml/min/1.73 m2)  76.5 ± 29.6  77.3 ± 15.7  45.6 ± 11.0  40.5 ± 12.9  < 0.001 
  Brain natriuretic peptide (pg/mL)  94.5 ± 118.1  134.9 ± 162.2  159.7 ± 176.7  242.4 ± 467.3 < 0.001 
Medications                        
  ACE inhibitor (%)  40.9  50.3  43.5  39.4  0.01 
  ARB (%)  30.7  27.2  37.4  40.9  < 0.001 
  Beta blocker (%) 43.0  49.7  44.4  44.8  0.20  
  Calcium channel blocker (%)  41.8  48.0  48.4  59.3  0.03 
  Loop diuretics (%)  32.8  34.8  52.3  52.8  < 0.001 
  Furosemide dose (mg)  6.8 ± 13.7  8.7 ± 17.0  12.6 ± 19.2  13.4 ± 19.1  < 0.001 
  Aldosterone inhibitor (%)  14.1  16.1  23.8  17.4  < 0.001 
  Statin (%)  40.1  35.7  41.8  43.3  0.17  
Outcome                        
  Follow-up period (yrs.)  2.5 ± 1.0  2.3 ± 1.0  2.5 ± 1.0  2.3 ± 1.1  < 0.001 
  All-cause death (%)  3.3  9.0  11.0  18.1  < 0.001 
  Cardiovascular death (%)  1.0  3.2  5.5  6.7  < 0.001 
HF, heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVDd, left 
ventricular end-diastolic diameter; GFR, glomerular filtration rate; ACE, angiotensin-converting enzyme; ARB,  
angiotensin II receptor blocker.  Numerical data are shown as mean ± standard deviation.  
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Table 2.  Cox proportional hazard model for all-cause death, cardiovascular death, and non-cardiovascular death 
                                                        
  
eGFR 
<60 
  
Dipstick 
  
No. of  
events 
(%) 
No. of  
events 
/100 
person /year 
(a) Unadjusted   (b) Age- and Sex- adjusted  (c) All baseline adjusted  (d) Fully adjusted including treatment HR Categories     
    HR 95% CI P value   HR 95% CI P value  HR 95% CI P value  HR 95% CI P value 
All-cause death                < 0.001         < 0.001         < 0.001         < 0.001 
  Group 1 (reference) - - 34 (3.3) 1.5  1.00           1.00          1.00         1.00         
  Group 2 - + 31 (9.0) 4.0  3.02  1.85  - 4.91  < 0.001  2.60  1.59 - 4.24  < 0.001  2.57 1.56 - 4.25  < 0.001  2.44  1.47 - 4.05 0.001  
  Group 3 + - 78 (11.0) 4.4  3.39  2.26  - 5.07  < 0.001  2.07  1.37 - 3.13  0.001   1.46 0.94 - 2.27  0.09   1.43  0.92 - 2.23 0.12  
  Group 4 + + 70 (18.1) 7.9  6.00  3.98  - 9.04  < 0.001  3.78  2.48 - 5.74  < 0.001  2.63 1.67 - 4.13  < 0.001  2.71  1.72 - 4.27 < 0.001 
                                                          
Cardiovascular death                < 0.001         < 0.001         < 0.001         < 0.001 
  Group 1 (reference) - - 10 (1.0) 0.4  1.00           1.00          1.00         1.00         
  Group 2 - + 11 (3.2) 1.4  3.65  1.55  - 8.59  0.003   3.30  1.40 - 7.80  0.006   3.66 1.53 - 8.72  0.003   3.58  1.50 - 8.58 0.004  
  Group 3 + - 39 (5.5) 2.2  5.72  2.85  - 11.45  < 0.001  3.68  1.80 - 7.49  < 0.001  2.34 1.13 - 5.09  0.023   2.34  1.10 - 4.98 0.03  
  Group 4 + + 26 (6.7) 2.9  7.53  3.63  - 15.63  < 0.001  5.06  2.40 - 10.60 < 0.001  3.25 1.47 - 7.18  0.004   3.29  1.48 - 7.31 0.003  
                                                          
Non-cardiovascular death              < 0.001         < 0.001         < 0.001         < 0.001 
  Group 1 (reference) - - 24 (2.3) 1.1  1.00           1.00          1.00         1.00         
  Group 2 - + 20 (5.8) 2.6  2.75  1.52  - 4.98  0.001    2.29  1.26 - 4.16  0.007   2.03 1.09 - 3.78  0.026   1.89  1.01 - 3.54 0.048  
  Group 3 + - 39 (5.5) 2.2  2.41  1.45  - 4.01  0.001    1.42  0.84 - 2.40  0.18   1.06 0.61 - 1.86  0.83   1.05  0.60 - 1.84 0.88  
  Group 4 + + 44 (11.4) 5.0  5.37  3.26  - 8.83  < 0.001   3.24  1.95 - 5.40  < 0.001  2.41 1.39 - 4.19  0.002   2.51  1.44 - 4.37 0.001  
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HR, hazard ratio; CI, confidence interval.  In the model (･)･ I adjusted the model by age, sex, and clinical status (NYHA class, systolic blood pressure, heart rate, body mass index, LVEF), serum sodium, 
serum potassium, history of admission for heart failure, and comorbidities (diabetes, hyperuricemia, anemia, coronary artery disease, cerebrovascular disease, atrial fibrillation, 
malignant tumor) and five urine dipstick test brands.  In the model (d), in addition to the model (c), I adjusted the model by treatment (beta blocker, angiotensin converting enzyme blocker, 
angiotensin II receptor blocker, calcium channel blocker, loop diuretics, aldosterone antagonist). 
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Figure 1. 
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Figure 2. 
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Figure 3. 
 
 
